Hundreds of researchers who saw their National Institutes of Health-funded studies halted by the Trump administration could begin working again soon after a federaljudge ordered their funding restored Monday.
Why it matters: The ruling was the latest blow to HHS Secretary Robert F. Kennedy Jr.'s efforts to reshape the agency, including cutting funding for research and institutions that it says do not support the agency's mission, such as diversity, equity and inclusion studies.
Dermatologists had hoped that an active sunscreen ingredient popular in Europe would be available in the U.S. by summer — but the Food and Drug Administration still hasn't approved it.
Why it matters: U.S. sunscreens lack some of the advanced UVA protection found in international brands, due to outdated FDA regulations, experts say.
A federal judge Monday ordered the National Institutes of Health to restore grants that the agency cut based on gender ideology or diversity, equity and inclusion, calling the terminations illegal.
Attorneys general from 55 U.S. states and territories signed onto a $7.4 billion settlement with Purdue Pharma and the Sackler family for their role in the country's opioid epidemic, officials said Monday.
Why it matters: The settlement, first announced in January, ends the Sackler family's control of Purdue Pharma and prohibits them from selling opioids in the country going forward, per state officials.
Anne Wojcicki is poised to regain controlof genetics testing company 23andMe, which she cofounded and led until earlier this year, after agreeing to put much of her personal fortune on the line.
Why it matters: This is the same person that 23andMe customers originally trusted with their personal data, albeit under a much more opaque governance structure.
President Trump's first-term surgeon general thinks people shouldn't be focused as much on who Health Secretary Robert F. Kennedy appointed to the expert panel that advises the Centers for Disease Control and Prevention on vaccine policy as the way he purged all 17 of the sitting members.
What they are saying: "Everyone jumped so quickly from 'they fired everybody' to 'let's talk about these new people' that we stopped talking about the fact that they fired everybody," said Jerome Adams, an anesthesiologist who's now a professor at Purdue University.
The Food and Drug Administration will miss a deadline this week deciding whether to approve a drug for a potentially life-threatening genetic disorder because of "heavy workload and limited resources," manufacturer KalVista Pharmaceuticals said.
Why it matters: It appears to be the first time an FDA review had to be extended because of DOGE-directed cuts to staff at the agency.
National Institutes of Health director Jay Bhattacharya didn't aggressively push back and defend Trump administration budget cuts and grant freezes when senators grilled him last week about plans for his agency.
An $18 billion cut in the 2026 NIH budget request was just a starting point for negotiations, he said.
